MCF-7
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
MCF-7 |
Humane Brust Karzinom Zell-Linie |
300273 |
cryovial |
265,00 |
MCF-7 |
Humane Brust Karzinom Zell-Linie |
330273 |
vital |
335,00 |
| Designation: | MCF-7 |
| Depositor: | McGrath |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Caucasian |
| Age/Stage: | 69 years old |
| Gender: | female |
| Tissue: | Breast |
| Morphology: | Epithelial-like |
| Growth Properties: | monolayer |
| Description: | Established from the pleural effusion of a patient suffering from a breast adenocarcinoma. The MCF-7 line retains several characteristics of differentiated mammary epithelium including ability to process estradiol via cytoplasmic estrogen receptors and the capability of forming domes. The cells contain the Tx-4 oncogene. The cells express the wildtype and variant estrogen receptors as well as progesterone receptor. Growth of MCF-7 cells is inhibited by tumor necrosis factor alpha (TNF alpha). Secretion of IGFBP's can be modulated by treatment with anti-estrogens. |
| Culture Medium: | DMEM:Ham's F12 supplemented with 2 mM L- glutamine and 10% fetal bovine serum. |
| Subculturing: | Remove medium and rinse with fresh 0.02% EDTA solution. Add fresh 0.025% trypsin/0.03% EDTA solution let the culture sit at 37°C until cells detach. Add fresh medium, centrifuge, resuspend in fresh medium and dispense into new flasks. Subculture every 6 to 8 days. |
| Split Ratio: | A ratio of 1:3 to 1:6 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | Yes, in nude mice |
| Oncogene: | wnt7h + |
| Karyotype: | The stemline chromosome numbers ranged from hypertriploidy to hypotetraploidy, with the 2S component occurring at 1%. There were 29 to 34 marker chromosomes per S metaphase; 24 to 28 markers occurred in at least 30% of cells, and generally one large submetacentric (M1) and 3 large subtelocentric (M2, M3, and M4) markers were recognizable in over 80% of metaphases. No DM were detected. Chromosome 20 was nullisomic and X was disomic. |
| Antigen Expression: | Blood Type O; Rh+ |
| Receptors Expressed: | estrogen |
| Isoenzymes: | PGM3, 1; PGM1, 1-2; ES-D, 1-2; AK-1, 1; GLO-1, 1-2; G6PD, B; Phenotype Frequency Product: 0.0154 |
| Products: | insulin-like growth factor binding proteins (IGFBP) BP-2; BP-4; BP-5 |
References: Soule HD et al. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-16, 1973. Brandes LJ et al. Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol. Cancer Res 43: 2831-5, 1983. Sugarman BJ et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-5, 1985. Lan MS et al. Polypeptide core of a human pancreatic tumor mucin antigen. Cancer Res 50: 2997-3001, 1990. Takahashi K et al. Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF- 7 cells. Int J Cancer 55: 453-8, 1993. Pratt SE et al. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-8, 1993. Umekita Y et al. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93: 11802-7, 1996. Zamora-Leon SP et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci USA 93: 1847-52, 1996. Jang SI et al. Activator protein 1 activity is involved in the regulation of the cell type-specific expression from the proximal promoter of the human profilaggrin gene. J Biol Chem 271: 24105-14, 1996. Lee JH et al. The proximal promoter of the human transglutaminase 3 gene. J Biol Chem 271: 4561-8, 1996. Chang K et al. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93: 136-40, 1996. Zhu X et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 93: 6091-5, 1996. Bellet D et al. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res 57: 516-23, 1997. Littlewood-Evans AJ et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57: 5386-90, 1997. Komarova EA et al. Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res 57: 5217-20, 1997. Van Dijk MA et al. A functional assay in yeas for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma. Cancer Res 57: 3478-85, 1997. Landers JE et al. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-8, 1997. Geiger T et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 13: 35-45, 1998. Prosperi JR et al. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp 19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 81: 55-70, 2006. Foster PA et al. In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clin Cancer Res 12: 5543-5549, 2006. | |
